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ABSTRACT
Purpose. To investigate the influence of the introduction
of total mesorectal excision (TME) on local recurrence rate
and survival in patients with rectal cancer.
Methods. A total of 171 consecutive patients underwent
anterior or abdominoperineal resection for primary rectal
cancer. When the TME technique was introduced, the
clinical setting, including the surgeons, remained the same.
Group 1 (1993–95, n = 53) underwent conventional sur-
gery and group 2 (1995–2001, n = 118) underwent TME.
All patients were followed for 7 years or until death.
Results. Between the two groups, no statistically signifi-
cant differences were present with regards to patient-,
treatment-, or tumor-related characteristics apart from the
time point of radiotherapy. The total local recurrence rates
were 11 of 53 (20.8%) in group 1 and 7 of 118 (5.9%) in
group 2, and the rates of isolated local recurrences were 6
of 53 (11.3%) in group 1 and 2 of 118 (1.7%) in group 2.
Both differences were highly statistically significant. The
disease-free survival in groups 1 and 2 was 60.4 and 65.3%
at 5 years, and 58.5 and 65.3% at 7 years, respectively.
Excluding patients with synchronous or metachronous
distant metastasis from the analysis, both the disease-free
survival and the cancer-specific survival were statistically
significantly better in group 2 than in group 1. No statis-
tically significant difference between the two groups was
detected regarding the overall survival.
Conclusions. The introduction of TME led to an impres-
sive reduction of the local recurrence rate. Survival is
mainly determined by the occurrence of distant metastasis,
but TME seems to improve survival in patients without
systemic disease.
Total mesorectal excision (TME) has become a widely
accepted modality for major resection of rectal cancer.1,2
The technique of TME has been described in detail pre-
viously, and its principles should be familiar to every
surgeon currently performing rectal cancer surgery.3,4 No
randomized studies are available that compare conven-
tional rectal cancer surgery with TME, most probably as a
result of the obvious advantages of TME. Several spe-
cialized centers reported in their TME series a local
recurrence rate of below 10%, whereas conventional rectal
cancer surgery has local recurrence rates of 20–30%.5–9
However, little is known about the impact of introduction
of TME in an established surgical team that performed
conventional rectal cancer surgery and then switched to
TME.10,11
The influence of TME on the oncological long-term
outcome has, so far, been poorly investigated. Most of the
TME studies report a median follow-up of 5 years or
less.7,11–15 However, an analysis of 169,658 French
patients with colorectal cancer who were initially treated
with curative intent estimated that the time to cure is
9.3 years.16 Similarly, a Japanese group found cumulative
recurrence rates in rectal cancer of 89% at 5 years, 98% at
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7 years, and 100% at 10 years.17 Therefore, any reliable
statement with regard to recurrence and survival in rectal
cancer needs a minimum follow-up of 7 years for every
patient operated with curative intent. This might be espe-
cially true for TME patients because the potentially
residual local tumor burden is estimated to be small and
therefore might need time to manifest as local recurrence.
There are a number of further issues in the current lit-
erature on TME. For example, studies on TME written in
Chinese are difficult to read by nonnative speakers.18 Some
studies were confounded by irradiation.19,20 In some, the
analyzed patients originated from randomized trials with
other study aims or from highly specialized institutes,
which might be biased.5,6,21,22 There are only a few pop-
ulation- and surgeon-based reports on the influence of
introduction of TME, although they are probably the best
reflection of daily practice.15,23 One of them, by perform-
ing a subgroup analysis, showed a survival advantage after
introduction of TME, but no data on local recurrence rate
were available.23 The limit of another study was that the
follow-up ended after 5 years.15
The present study aimed to investigate the impact of the
introduction of TME on the reduction of the local recur-
rence rate in a stable clinical setting, meaning the same
surgical staff, medical institution, and population. In
addition, because the follow-up for every one of our
patients with resected rectal cancer was at least 7 years,
this study is a reliable statement of the impact of TME on
long-term outcome.
PATIENTS AND METHODS
Within the period of the last author’s chairmanship
(M.W.B.) at the University Hospital of Berne, from
November 1993 until October 2001, a total of 194 patients
with rectal cancer underwent surgery in his department.
Rectal cancer was defined as histologically proven adeno-
carcinoma at or below 15 cm from the anal verge,
measured with a rigid rectoscope. The data from all
patients were consecutively and prospectively recorded in a
computerized database.
Thirteen of 194 patients had no resection of the primary
due to locally or systemically far advanced disease (nine
patients with International Union Against Cancer [UICC]
stage IV disease and four patients with stage III disease
and/or high operative risk), giving a resectability rate of
93.3%. Seven patients refused regular follow-up or were
lost. Three patients had local excision of an early cancer
via a transanal or a posterior approach. The patients of
these 3 subgroups were excluded from further analysis,
leaving a study population of 171 patients with low anterior
resection or abdominoperineal resection and complete
follow-up. These 171 patients were further divided into two
groups, one before the introduction of the TME technique
(group 1, from November 1993 until July 1995) and the
other after (group 2, from July 1995 until October 2001).
Patient-, treatment-, and tumor-related characteristics of
the total study collective as well as of groups 1 and 2
separately are listed in detail in Table 1. Patients with
rectal cancer of stage II or III according to UICC criteria
were recommended to undergo (neo)adjuvant radioche-
motherapy. Exclusions for adjuvant treatment were
protracted infectious complications of the tumor or of the
surgery, and usually the tumor site within the upper third of
rectum. The neoadjuvant treatment consisted of short-
course radiotherapy (5 9 5 Gy per week) followed by
immediate surgery if the aim of radiotherapy was sterili-
zation of intrapelvic micrometastasis, or radiotherapy
45–50.4 Gy per 5–6 weeks combined with 5-fluorouracil
infusion followed by surgery with a delay of 4–6 weeks if
the primary aim of radiotherapy was to downsize the
intrapelvic tumor. The schedule of the postoperative
radiotherapy was 45–50.4 Gy over 5–6 weeks, applied in
single doses of 1.8 Gy, and combined with 5-fluorouracil
infusion.
The conventional rectal excision (group 1) consisted of a
dissection of the superior rectal artery or the inferior
mesenteric artery and further preparation toward the pelvis
directly on the aortic bifurcation and the common iliac
arteries. Mobilization of the rectum at the dorsal aspect was
done bluntly by the surgeon’s hand or fingers, whereas the
mesorectum laterally on both sides was sharply dissected
between clamps and suture stitches. Anteriorly, either
sharp or blunt dissection was used. No attention was paid to
preserve the autonomic nerve structures.
The TME technique as described by Heald et al. was
introduced in our institution in July 1995.3 For this, the staff
surgeons from our department who usually performed rectal
resections visited Bill Heald in Basingstoke to watch him
perform TME. They learned the TME technique from his
videos and from several interactive workshops with him.
Briefly, complete removal of the mesorectum and the
mesentery containing the inferior mesenteric artery and
vein and the main locoregional lymphatic system of the
rectum could be achieved by meticulous sharp dissection of
the avascular plane, the so-called holy plane, between
parietal and visceral pelvic fascia.24 Anteriorly, the speci-
men included the intact Denonvilliers fascia and the
peritoneal reflexion. Autonomic nerve structures were
preserved. Little autonomic nerves branching off the infe-
rior hypogastric plexus directly into the rectum as well as
the middle rectal artery, if present, needed to be cut. No
clamps were used to control blood vessels. The resection
plane was extended laterally in locally advanced rectal
tumors only if tumorous adherence or infiltration of the
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visceral pelvic fascia occurred, always with the goal of
obtaining a clear lateral resection margin. Before dissection
of the rectum distally, a rectangle clamp was placed on the
mobilized rectum distally to the tumor, and a rectal stump
washout was performed.25 Both manoeuvres should help to
avoid tumor cell contamination and consecutive tumor
seeding. Within group 2, all tumors of the middle or lower
third of the rectum were treated with a TME; tumors of the
upper third were removed by a (longitudinally) partial
mesorectal excision. Care was taken to preserve the pelvic
autonomic nerve structures.26
Colorectal or coloanal reconstruction was performed by
using the descending or transverse colon as a straight
colonic section, as a colon J pouch, or as a transverse co-
loplasty pouch. The transverse coloplasty pouch was
developed in an animal model by our group and was later
adopted in humans.27,28 All anastomoses at or below 6 cm
from the anal verge were protected by a temporary loop
ileostomy. All patients received a preoperative orthograde
bowel preparation. An omental patch was placed into the
sacral cavity to reduce the risk of pelvic abscesses. In
group 2, the TME technique was also used for patients
needing an abdominoperineal resection. In both groups,
abdominoperineal resection was performed without wide
excision of the anal sphincter muscle and the pelvic floor.
Indications for abdominoperineal resection were tumorous
infiltration of the external anal sphincter muscle and/or the
puborectal sling, if known from pretreatment investigations
or detected intraoperatively.
Early in 1997, our pathologists started to investigate the
circumferential resection margin according the method
published by Quirke et al.29,30 In brief, the rectal specimen
including the mesorectum were sent unopened to pathology.
The circumferential resection margin of the mesorectum
were marked with ink. After fixation in formalin, the speci-
men was then cut in 5-mm slices and documented by
photographs. From sites where the tumor grossly reached
near the circumferential resection margin or where the
mesorectal fascia was damaged, a meticulous microscopic
workup was performed. An R1 resection was defined as the
distance between the cancer and the circumferential or distal
resection margin of less than 1 mm.30
Patients were in a regular surveillance program
according to the guidelines of the Swiss Society of Gas-
troenterology established in 1996 and slightly modified in
2001, 2004, and 2007.31 Before 1996, our own and even
more intensive follow-up schedule was used. All versions
recommended at least the following examinations: clinical
examination and serum carcinoembryonic antigen mea-
surement every 6 months during the first 2 years and yearly
thereafter; rectosigmoidoscopy and rectal endosonography
(if available) every 6 months during the first 2 years;
complete colonoscopy after 3 or 4 years, then every
5 years; and liver ultrasound or thoracoabdominal
TABLE 1 Patient-, treatment-, and tumor-related characteristics
Characteristic Total
(n = 171)
Group 1 (conventional)
(n = 53)
Group 2 (TME)
(n = 118)
P (group 1 vs.
group 2)
Sex 0.35
Female 59 21 38
Male 112 32 80
Median (range) age at operation (year) 65.6 (33.4–89.6) 64.5 (33.4–85.4) 66.8 (34.4–89.6) 0.29
Median (range) tumor diameter (cm), measured
after fixation in formalin
4.0 (0.5–9.5) 4.5 (0.5–9.5) 4.0 (0.5–9.0) 0.24
Median (range) distance of tumors from anal verge (cm) 8.0 (1.0–15.0) 8.0 (2.0–15.0) 8.0 (1.0–15.0) 0.62
Type of operation 0.38
(Low) anterior resection, n (%) 142 (83.0) 42 (79.3) 100 (84.7)
Abdominoperineal resection, n (%) 29 (17.0) 11 (21.7) 18 (15.3)
UICC tumor stage 0.33
I 53 (31.0) 18 (34.0) 35 (29.7)
II 31 (18.1) 13 (24.5) 18 (15.3)
III 51 (29.8) 12 (22.6) 39 (33.1)
IV 36 (21.1) 10 (18.9) 26 (22.0)
Preoperative radiotherapy, n (%) 19 (11.1) 1 (1.8) 18 (15.3) 0.01
Postoperative radiotherapy, n (%) 16 (9.4) 9 (17.0) 7 (5.9) 0.02
Total irradiated patients, n (%) 35 (20.5) 10 (18.9) 25 (21.2) 0.73
Postoperative chemotherapy, n (%) 66 (38.6) 19 (35.8) 47 (39.8) 0.62
UICC International Union Against Cancer
Long-Term Outcome after TME for Rectal Cancer 1901
computed tomographic scan annually for 3 years. Exam-
inations were intensified if recurrence was suspected. In
addition, the follow-up status of the patients regarding
recurrence, sites of recurrence, time to recurrence, survival,
and time of death were assessed by standardized reim-
bursed questionnaires sent to the treating physician or
oncologist, or by telephone conversations with these col-
leagues. All patients were followed for at least 7 years after
resection of their rectal cancer or until death.
The trial was approved by the local ethical committee
(KEK No. 08-05-09). It was registered at ClinicalTri-
als.gov, identification no. NCT00910143.
Results are expressed as means including standard errors
of mean or medians including the range. Differences
between the two groups (conventional surgery vs. TME)
regarding age, tumor diameter, distance of tumor from the
anal verge, distal safety margin, number of investigated
lymph nodes, and number of positive lymph nodes (quan-
titative data) were analyzed with a Mann–Whitney U-test.
Differences in the remaining patient, treatment, and tumor
characteristics (category data) in both groups were calcu-
lated by the v2 test. The importance of the factors
influencing local recurrence was compared by logistic
regression analysis. Survival analyses were performed by
the Kaplan-Meier method, and the importance of the fac-
tors influencing disease-free and overall survival was
compared by multivariate regression analysis. The statis-
tical significance was attributed at the 5% level. WinStat
version 5.3 and STATA 10.0 served as the computerized
statistical analysis systems.
RESULTS
The percentage of sphincter-saving procedures in the
whole series was 83.0%. One postoperative death occurred
at day 9 from cardiac arrest in an 82-year-old patient in
group 2.
The specific results related to surgical quality and on-
cosurgical radicality of the total study collective as well as
of groups 1 and 2 are summarized in Table 2. According to
the method of Kaplan–-Meier, the long-term outcomes of
both groups are depicted as disease-free survival (Fig. 1),
as overall survival (Fig. 2), as cancer-specific survival
(Fig. 3), and as cancer-specific survival excluding patients
with synchronous or metachronous distant metastases
(Fig. 4).
The disease-free survival excluding synchronous and
metachronous distant metastases was significantly better in
the TME group (P = 0.02).
Logistic regression analysis showed that the use of TME
(P = 0.001), R0 resection (P = 0.003,) and negative nodal
stage (P = 0.028) significantly reduced local recurrence
rate. Local tumor stage of \ T3 (P = 0.084), age (P =
0.931), male sex (P = 0.370), tumor diameter (P =
0.954), security distance (P = 0.296), distance to the anal
verge (P = 0.966), neoadjuvant therapy (P = 0.120),
adjuvant chemotherapy (P = 0.198), and adjuvant radio-
therapy (P = 0.134) did not have a significant impact on
the local recurrence rate.
Multivariate regression analysis showed that age
(P = 0.000) and UICC tumor stage IV (P = 0.000)
TABLE 2 Results for surgical quality, oncosurgical radicality, and long-term outcome
Characteristic Total
(n = 171)
Group 1 (conventional)
(n = 53)
Group 2 (TME)
(n = 118)
P (group 1 vs.
group 2)
Septic complications within the pelvis, n (%) 9 (5.7) 3 (5.7) 6 (5.1) 0.88
Median (range) distal safety margin (cm), measured
after fixation in formalin
3 (0.1–10.0) 3 (0.5–8.0) 3 (0.1–10.0) 0.24
Residual tumor (locoregional)
R1 resection, n (%) 9 (5.7) 4 (7.5) 5 (4.2) 0.37
Local R2 resection, n (%) 2 (1.2) 0 2 (1.7) 0.34
Median (range) no. of investigated nodes 12 (1–69) 9 (1–22) 13 (1–69) \0.001
Median (range) no. of positive nodes in node
positive patients
3.0 (1–20) (n = 78) 2.5 (1–10) (n = 18) 3.0 (1–20) (n = 60) 0.42
Recurrence
Local recurrence, total n (%) 18 (10.5) 11 (20.8) 7 (5.9) 0.003
Local recurrence, only n (%) 8 (4.7) 6 (11.3) 2 (1.7) 0.006
Distant metastasis, total, n (%) 59 (34.5) 17 (32.1) 42 (35.6) 0.65
Distant metastasis, only, n (%) 49 (28.7) 12 (22.6) 37 (31.4) 0.24
Disease-free survival after 5 years 63.7% 60.4% 65.3% 0.60
Disease-free survival after 7 years 63.2% 58.5% 65.3% 0.45
UICC International Union Against Cancer, TME total mesorectal excision, R1 microscopic residual tumor (at resection margin), R2 gross
(macroscopic) residual tumor
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significantly reduced overall survival, whereas the fol-
lowing factors had no significant impact on overall
survival: UICC tumor stage III (P = 0.070), UICC tumor
stage II (P = 0.220), UICC tumor stage I (P = 0.224),
distance to the anal verge (P = 0.811), tumor diameter
(P = 0.957), the use of low anterior rectum resection
versus abdominoperineal amputation (P = 0.490), the use
of TME (P = 0.483), R0 resection (P = 0.659), distant
margin (P = 0.127), perforation during operation
(P = 0.325), pelvic abscess (P = 0.965), neoadjuvant
therapy (P = 0.373), adjuvant chemotherapy (P = 0.675),
adjuvant radiotherapy (P = 0.345), male sex (P = 0.121),
and duration of hospitalization (P = 0.941).
Regarding disease-free survival, multivariate regression
analysis showed that age (P = 0.003), UICC tumor stage
III (P = 0.018), and UICC tumor stage IV (P = 0.000)
significantly reduced disease-free survival, whereas all the
other factors had no significant impact on disease-free
survival: UICC tumor stage II (P = 0.177) and UICC
tumor stage I (P = 0.250), distance to the anal verge
(P = 0.335), tumor diameter (P = 0.635), the use of low
anterior rectum resection versus abdominoperineal ampu-
tation (P = 0.979), the use of TME (P = 0.213), R0
resection (P = 0.533), distant margin (P = 0.051), perfo-
ration during operation (P = 0.420), pelvic abscess
(P = 0.866), neoadjuvant therapy (P = 0.676), adjuvant
Conventional
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FIG. 1 Disease-free survival
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FIG. 2 Overall survival
Conventional
TME
p = 0.64
1.0
0.8
0.6
0.4
0.2
960
Cancer-specific survival (months)
Percentage 
of disease-free 
patients (% × 100)
12 24 36 48 60 72 84
FIG. 3 Cancer-specific survival
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FIG. 4 Cancer-specific survival excluding patients with distant
metastasis
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chemotherapy (P = 0.602), adjuvant radiotherapy (P =
0.0621), male sex (P = 0.056), and duration of hospital-
ization (P = 0.853).
When we analyzed the potential impact of (neo)adjuvant
radiotherapy plus chemotherapy for patients with tumor
stages II and III, we found that the local recurrence rates
did not seem to improve by means of such a standard
treatment: in the conventional group, 4 out of 17 (23.5%)
patients not treated according to a standard protocol had
local recurrence, versus 3 of 8 (37.5%) patients treated, and
3 of 48 (6.3%) not treated versus 1 of 9 (11.1%) treated in
the TME group, respectively. When we stopped the sur-
vival analysis in both groups at 7 years or earlier death, the
mean disease-free survival in the conventional group was
49 months without standard therapy and 53 months with
standard therapy, and in the TME group 58 months without
standard therapy and 55 months with standard therapy.
In the conventional group, two of six patients with
isolated local recurrence could successfully undergo repeat
operation without developing a repeat recurrence, whereas
in the TME group, both patients with isolated local
recurrence died from it.
DISCUSSION
In a consecutive series of patients with rectal cancer, the
impact of the introduction of TME on pelvic recurrence
and survival was investigated. Both groups of patients, the
conventionally operated group and the TME group origi-
nated from the same population and were treated by the
same staff of surgeons within the same institution. In the
present series, the introduction of TME led to a highly
statistically significant decrease of the local recurrence
rate, from 20.8% in the conventional surgery group to 5.9%
in the TME group. Thus TME reduced the number of local
recurrences to below one third. Given the long follow-up
period of at least 7 years or until death for all patients,
these figures are reliable because more than 85% of all
local recurrences become detectable within 3 years after
primary surgery, and a recurrence-free period of 7 years is
regarded as a definite cure in more than 98% of colorectal
carcinomas.11,16,17
The analysis of patients with local recurrence only, as
sole site of recurrence, revealed local recurrence rates of
11.3% in the conventional group and 1.7% in the TME
group. Again, this surgical progress is highly statistically
significant and of the utmost importance because surgical
salvage procedures—if feasible at all—may be demanding,
mutilating, expensive, and ultimately not curative.32 Many
surgeons no doubt still have patients in mind who slowly
deteriorated over the course of years with painfully
invading local recurrence of rectal cancer.
Both groups showed similar patient and tumor charac-
teristics, with the exception that radiotherapy was
performed more often postoperatively in the conventional
group and more often preoperatively in the TME group.
This is a limitation of the study because preoperative
radiotherapy might have induced size reduction of tumors
and facilitated the dissection. One might argue that this
shift from mainly postoperative to preoperative radiother-
apy might have substantially contributed to the drop in
local recurrence rate in the TME group. Indeed, two ran-
domized trials have demonstrated an advantage for the
preoperative irradiation modus.33,34 By application of
irradiation to every patient in these studies, a reduction in
local recurrence rates in the preoperatively irradiated
patients of 9 and 7%, respectively, was observed.33,34 In
the present study, however, only 20% of all patients
received any radiotherapy at all. Therefore, the optimized
time point of irradiation in the TME group is estimated to
count for less than 2% reduction of the local recurrence rate
and may not explain the reduction of 15% found in our
study. Furthermore, the potential confounding factor of
different time points of radiotherapy was weakened by
logistic regression analysis, which showed TME to be the
most important factor in preventing local recurrence.
Despite the impressive reduction of the local recurrence
rate in the TME group, surprisingly, no statistically sig-
nificant difference in disease-free or overall survival could
be detected between the two groups. Several circumstances
specific to the present study may be responsible for this
fact. First, the initially advanced UICC tumor stages III and
IV were more frequent in the TME group than in the
conventional group. Second, in the TME group, the total
proportion of patients with synchronous or metachronous
distant metastasis exceeded the corresponding proportion
in the conventional group by 3.5%. Finally, patients in the
TME group were a median of 2.3 years older than in the
conventional group, leading to a possible negative impact
on overall survival. Indeed, 24.3% of the recurrence-free
patients died from another cause in the TME group during
the 7-year follow-up period, but only 20.0% did so in the
conventional group. These factors, taken together, might
have negatively influenced survival in the TME group
compared with the conventional group. However, in the
multivariate analysis, TME did not turn out to be a statis-
tically significant predictive factor of disease-free or
overall survival. Nevertheless, the TME group showed a
5% benefit for 5-year disease-free survival and a 7% ben-
efit for 7-year disease-free survival (Table 2, Fig. 1). These
differences might have become significant in a study with a
larger sample size, but the study had to be stopped at an
underpowered state of accrual because the first and last
authors departed the surgical department, which was
equivalent to a change in the study setting.23 Further,
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omission of (neo)adjuvant therapy in most patients with
stage II or III disease did not seem to be responsible for the
lack of improvement in survival of the TME group.
However, even these rather small disease-free and can-
cer-specific survival benefits in the TME group, when
compared to the conventional group, should support the
TME technique further because the beneficial effect of
TME in our study is almost as high as that of adjuvant
systemic chemotherapies. Furthermore, excluding patients
with synchronous or metachronous distant metastasis from
the analysis, both the disease-free survival and the cancer-
specific survival were statistically significantly better in the
TME group than in the conventional group.
Although not directly comparable, the Dutch TME trial
and other studies also failed to show an overall survival
benefit, despite an improved rate of local recurrence.15,21,34
Survival seems to be mainly determined by the occurrence
of distant disease. Laurent et al. found that patients with
postoperative pelvic sepsis had a 5-year survival rate of
39% compared with 65% without pelvic sepsis.7 They
hypothesized that the expected survival benefit by TME is
neutralized by an increased pelvic sepsis rate that is asso-
ciated with increased risk of distant recurrence and
decreased long-term survival. In the present study, how-
ever, a similarly low pelvic sepsis rate was encountered in
both groups, probably facilitated by the consequent use of a
pelvic omental patch and a defunctioning loop ileostomy
for all anastomoses below 7 cm from the anal verge.
In conclusion, within a stable study setting, the intro-
duction of TME led to a clear reduction of the local
recurrence rate in rectal cancer. After TME, local recur-
rences occurred exceptionally as the sole site of recurrence
but were almost always accompanied by distant metastasis.
The long-term follow-up of 7 or more years for all patients
revealed only a tendential survival benefit from TME,
probably as a result of a higher number of adverse factors
in group 2 than in group 1. Future therapeutic efforts
should be directed to control recurrences from distant
metastasis.
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